Eurobench.com

flosz 20 november 2015 18:26

0

twitter.com/williamgerber1/status/667...

Bijlage:

QLVT 23 november 2015 19:25

0

toch raar volume 1500 laat $19,15 ,koop 3 keer 200 om19.21 uur en de vollume blijft 1500.....

QLVT 23 november 2015 19:26

0

Sorry 100 200 100

flosz 1 december 2015 16:00

0

Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-FIX, First In Vivo Protein Replacement Platform Program For Treatment Of Hemophilia B
Study, Scheduled to Begin in 2016, Will Represent First Clinical Application of In Vivo Genome Editing

RICHMOND, Calif., Dec. 1, 2015 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for SB-FIX, a potentially curative, single treatment therapy for hemophilia B. SB-FIX is the first in vivo genome editing application to enter the clinic and is based on Sangamo's proprietary In Vivo Protein Replacement Platform™ (IVPRP™). The IND is now active and enables Sangamo to initiate a Phase 1/2 clinical study (SB-FIX-1501) designed to assess safety, tolerability and potential efficacy of SB-FIX in adults with hemophilia B.
investor.sangamo.com/releasedetail.cf...

flosz 2 december 2015 23:15

0

$SGMO case for integrating vs. non-integrating GT in hemophilia B vs $QURE. IND for Hurler Syndrome by YE. twitter.com/princetongb/status/672097...

Bijlage:

flosz 7 december 2015 10:20

0

twitter.com/bioterp/status/6732252525...

2040 Adeno-Associated Virus 8 (AAV8) Vector Genome Biodistribution into Body Fluids Following Single Intravenous Administration of BAX 335 Gene Therapy for Hemophilia B

Introduction: Gene therapy may provide long-term benefit in hemophilia B with a single administration. BAX 335 (AAV8.sc-TTR-FIXR338Lopt) delivers a self-complementary codon-optimized hyperactive F9 transgene (FIXR338Lopt), driven by the liver-specific transthyretin (TTR) promoter in an adeno-associated virus 8 (AAV8) capsid. Shedding is an area of concern with vectors of viral origin and must be evaluated as part of the regulatory application process.
Objective: A secondary objective of this ongoing, phase 1/2, open-label study is to determine the duration of BAX 335 genome shedding into blood, saliva, semen, urine, and stool after single-dose administration in subjects with hemophilia B. Results of an unplanned preliminary analysis of data on shedding from this study are presented.
Methods: Up to 16 adult men with severe hemophilia B are to be given a single intravenous dose of BAX 335 in up to 4 sequentially ascending dose cohorts: Cohort 1 (2.0x1011 vector genome [vg]/kg), Cohort 2 (1.0x1012 vg/kg), Cohort 3 (3.0x1012 vg/kg), and Cohort 4 (4.0x1012 vg/kg). A quantitative real time polymerase chain reaction (qPCR) is used to detect vector genomic DNA sequences (BAX 335 genomes) in body fluids collected from each subject. Whole blood, saliva, semen, urine, and stool samples are obtained before study drug administration; on day 1; at weeks 1, 2, and 3; and at weekly intervals thereafter until negative (2 consecutive samples below limit of detection).
Results: The study is ongoing and preliminary results are available for 7 subjects (S1-S7; Table). All subjects were negative for BAX 335 genomes in all samples at screening. In blood, BAX 335 genomes were detected at the first weekly visit in all subjects, with peak levels achieved at that time. BAX 335 genomes were considered negative in blood between 5 and 9 months after treatment in the 4 subjects (S1-4) for whom follow-up is complete. The remaining 3 subjects (S5-S7) have not yet achieved a negative result in blood (S5) or have not yet reached the month 9 visit (S6 and S7) at the time of this abstract and are still being followed (Table). BAX 335 genomes were also identified at lower levels in saliva (n=7), semen (n=5), stool (n=7), and urine (n=4), with peak values achieved between 1 day and 2 weeks and persisting for 1-5 weeks. The safety profile for all subjects enrolled to date was acceptable, including no inhibitors to factor IX (FIX).
ash.confex.com/ash/2015/webprogram/Pa...

Bijlage:

flosz 7 januari 2016 13:36

0

uniQure Announces Preliminary Topline Results from Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Trial

--Meaningful Factor IX Expression Validates Successful Transduction of the Liver Using uniQure’s Proprietary AAV5 Vector--

--Four of Five Patients Have Fully Discontinued Prophylactic Recombinant Factor IX Therapy--
--Conference Call to Discuss Data Scheduled for 8:30 am EST Today, January 7--

Amsterdam, the Netherlands, January 7, 2016 —uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced preliminary topline results from the low-dose cohort of an ongoing Phase I/II clinical trial being conducted in adult hemophilia B patients treated with uniQure’s novel AAV5/FIX gene therapy, AMT-060. All five patients in the low-dose cohort had Factor IX (FIX) phenotypic features of severe or moderately-severe hemophilia including documented Factor IX (FIX) levels less than 1-2% and required chronic treatment with prophylactic recombinant FIX (rFIX) therapy at the time of enrollment.
The first two patients out of five in the low dose cohort have completed at least 20 and 12 weeks of follow up and had central-lab-confirmed FIX expression levels of 5.5% and 4.5% of normal, respectively at the cutoff date of December 16th, 2015. The three additional patients have been dosed, but had not achieved the full 12 weeks of follow-up at the cutoff date. However, as of January 6, 2016, four of the five patients, including the first two patients enrolled in the study, have met a secondary objective in the trial by fully discontinuing prophylactic rFIX. The 12 week follow-up, post AMT-060 administration, marks the period in which investigators in the trial attempt discontinuation of prophylactic rFIX, based on FIX expression levels. The first patient in the low-dose cohort experienced a mild, transient and asymptomatic elevation of transaminase levels at around 10 weeks post treatment. This patient received a short, 8-week course of tapering prednisolone doses with rapid return of transaminase levels to baseline values. No elevated transaminase levels have been observed in the other four patients thus far, with all patients being on therapy for at least 10 weeks as of January 6, 2016.
AMT-060 consists of a codon-optimized wild type FIX gene and the LP1 liver promoter together with the AAV5 viral vector, manufactured using uniQure’s proprietary insect cell based manufacturing technology. AMT-060 is administered, without immunosuppressant therapy, through the peripheral vein in one treatment session for approximately 30 minutes. The study includes two cohorts, with the low-dose cohort using 5x1012 gc/kg and the high-dose cohort using 2x1013 gc/kg. Thus far, there have been no patient screening failures due to pre-existing neutralizing antibodies against AAV5 and no patients have developed inhibitory FIX antibodies.
These early data from the low-dose cohort suggest that AMT-060 is generally well-tolerated and capable of successfully transducing the liver resulting in clinically meaningful FIX expression levels. This current trial uses a starting dose of AAV5/FIX gene therapy that is similar to the highest dose of the same FIX gene cassette evaluated in a study conducted by Prof. Amit Nathwani and the St. Jude Children’s Hospital using an AAV8 serotype vector, and uniQure’s preliminary data are comparable with the endogenous FIX expression levels achieved in the St. Jude study. The results of the St. Jude study, which were published in the New England Journal of Medicine in 2011 and 2014, demonstrated that a durable mean FIX expression of 5.1% of normal (range 2.9% to 7.2%) can be achieved with this gene cassette and result in meaningful long-term clinical benefits for patients. In the St. Jude study, four of six patients treated at the high dose had transient elevations of transaminase levels, managed with a tapering prednisolone regimen. The FIX gene cassette used in the St. Jude study is exclusively licensed by uniQure.
“Thus far, the overall tolerability and FIX expression profile in the low-dose cohort is encouraging for patients with hemophilia B and support the continuation of the study,” commented Professor Frank W.G. Leebeek, M.D. Ph.D. of the Erasmus Medical Center in Rotterdam, an investigator in the study. “Previous studies have demonstrated that maintaining durable FIX expression around 3% to 5% of normal may have a significant clinical benefit as measured by significant reduction in consumption of units of FIX concentrate and lower risk of spontaneous bleeding episodes.”
uniQure intends to present a more complete analysis of these data from this low-dose cohort at a scientific conference in the second quarter of 2016. Subject to the Data Monitoring Committee’s approval, the Company also anticipates initiating enrollment of the high-dose cohort this quarter.
“These preliminary topline results support our hypothesis that AAV5/FIX can deliver clinically meaningful expression levels of FIX for patients with hemophilia B,” commented Dan Soland, Chief Executive Officer of uniQure. “So far, our AAV5-based gene therapies have been systemically administered to 13 adult patients across two clinical studies in two different disease states, and via direct central nervous system administration in four children in a third study, providing us with a strong safety dataset on the AAV5 vector and our proprietary insect cell based manufacturing technology.”
“Today, we are the only AAV gene therapy company in the world with both proprietary, commercial-scale manufacturing capabilities and encouraging clinical data across multiple diseases,” continued Mr. Soland. “These preliminary results further support our modular platform approach and leadership in gene therapy.”

Slides: www.uniqure.com/uploads/AMT-060%20Sli...

Bijlage:

flosz 7 januari 2016 15:48

0

UniQure's Gene Therapy Boosts Clotting in Two Hemophiliacs

* Factor IX levels rose to 4.5% and 5.5% of what is normal?
* Gene therapy would compete with Pfizer, Biogen products?

UniQure NV, the Dutch biotechnology company that developed the first gene therapy approved in Europe, said its experimental treatment for hemophilia B increased blood clotting ability in two patients. The shares rose as much as 21 percent in trading before U.S. markets opened.
The therapy, known as AMT-060, was designed to fix a genetic flaw caused by missing or defective factor IX, a protein that clots blood. The two adult patients received a low dose of the treatment. Factor IX rose to 5.5 percent and 4.5 percent of the normal level from less than 2 percent in the patients, the company said in a statement Thursday. Three other people who received a low dose of the therapy in the trial haven’t yet reached the full 12 weeks of follow-up, UniQure said.
UniQure rose as high as $18.10 in pre-market trading, up from its Wednesday closing price of $14.91.

Factor IX levels of more than 5 percent are considered a mild form of the disease, which results in bleeding happening only rarely, according to Gbola Amusa, an analyst at Chardan Capital Markets LLC in New York who recommends buying UniQure shares. The company plans to start enrolling patients who will receive a higher dose of the therapy in the trial this quarter.
Mixed Results
Gene therapies have shown mixed results in recent months. Spark Therapeutics Inc. said in October its treatment for rare form of blindness improved patients’ sight, while Bluebird Bio Inc. shares plunged the most ever in December after a company trial of a sickle cell disease therapy disappointed investors.
Current treatments for hemophilia B involve regular self-injections of the missing clotting factor IX to prevent prolonged internal and external bleeding episodes in case of injury. The market leader is Pfizer Inc.’s BeneFix, followed by Biogen Inc.’s Alprolix. Novo Nordisk A/S, which also makes a competing product, said Thursday it filed for approval of a long-acting factor IX product to European regulators.
Available treatments cost $300,000 to $440,000 a year in the U.S. and can be as high as $1 million a year in some patients, according to Amusa. Hemophilia B can cost the health system more than $20 million per patient when medicines, doctors, nurses, and hospital storage are included in the bill, he said.

Therapy Costs
The cost of the gene therapy should be compared with other orphan drugs that target rare diseases, which on average cost about $250,000 a year, according to Joern Aldag, who stepped down as UniQure’s chief executive officer last month. Given the expense, UniQure and other developers have considered alternative forms of reimbursement. For example, payments may be spread out over several years and could cease if a patient dies, Aldag said last year.
UniQure also developed Glybera, which treats a potentially fatal genetic disease that results in acute swelling of the pancreas. Glybera in 2012 became the first gene therapy approved for use in Europe. UniQure is also partnered with Bristol-Myers Squibb Co.on a therapy for congestive heart failure.
UniQure in December said Dan Soland, former chief operating officer of ViroPharma Inc., would succeed Aldag.

twitter.com/maki_kitamura/status/6850...

flosz 12 januari 2016 09:22

0

twitter.com/festivus159/status/686692...

Bijlage:

Prof. Dollar 12 januari 2016 09:50

1

quote:
flosz schreef op 12 januari 2016 09:22:
twitter.com/festivus159/status/686692...

Het was mij al eerder opgevallen:
twitter.com/Prof_Dollar/status/676478...

;-)

flosz 12 januari 2016 10:18

0

Haha, proof: een maand er tussenuit is echt een maand er tussenuit.

[verwijderd] 28 januari 2016 17:43

1

Bericht had ik natuurlijk hier moeten plaatsen: www.nu.nl/gezondheid/4205484/eerste-s...

flosz 28 januari 2016 18:22

0

Berichtgeving AMC erbij:

De levercellen die het nieuwe DNA hebben opgenomen, kunnen worden afgebroken door het afweersysteem, waardoor ook de factor IX eiwitproductie weer verloren gaat. Tot nu toe – de AMC-patiënt is in september vorig jaar behandeld – is dat nog niet gebeurd. ?Coppens is dan ook voorzichtig optimistisch: “Als onze studie langdurige expressie laat zien van stollingsfactor IX, dan zou dit wel eens dé behandeling voor deze ziekte kunnen zijn. Maar dan moet blijken dat het een therapie is waarbij de meeste patiënten geen immuunreactie ontwikkelen in de eerste drie maanden en gedurende een lange periode het stollingseiwit produceren.”

Eerste succes gentherapie bij hemofiliepatiënt AMC
28 januari 2016
Voor het eerst is bij een hemofiliepatiënt in Nederland succes geboekt met gentherapie. De patiënt is niet genezen, maar de ziekte is daardoor voorlopig teruggebracht van een ernstige naar een milde vorm. Dat maakt een enorm verschil: in plaats van twee keer per week een bloedtransfusie met stollingsfactor IX is er slechts in uitzonderlijke situaties een transfusie nodig. Bovendien heeft de patiënt vrijwel geen gewrichtsbloedingen meer, waardoor de gewrichten niet langer door de hemofilie zullen verslijten. Het is afwachten of het effect lang aanwezig blijft; de onderzoekers zijn voorzichtig optimistisch.
De patiënt – die aan hemofilie B lijdt – is in studieverband behandeld in het AMC. Het onderzoek wordt geleid en gefinancierd door het biotechbedrijf UniQure, dat is gevestigd op het terrein van het AMC. In totaal zullen er tien patiënten meedoen aan de studie – verdeeld over vier Nederlandse ziekenhuizen en centra in Duitsland, Denemarken en Italië.?Hemofilie B is een ziekte waarbij het bloed niet goed kan stollen door afwezigheid van stollingsfactor IX. Door een defect gen wordt dit eiwit onvoldoende aangemaakt. Behandeling met gentherapie houdt in dat een goed werkend exemplaar van het defecte gen wordt ingebouwd in de levercellen van de patiënt. Hierdoor wordt het ontbrekende eiwit wél geproduceerd. ?Het vinden van het juiste vervoermiddel (vector) voor het nieuwe, goed functionerende gen is de grootste uitdaging. Vasculair internist Michiel Coppens, in het AMC hoofdonderzoeker gentherapie bij hemofilie B: “Voor hemofilie B denken we een goed vervoermiddel te hebben gevonden waardoor het nieuwe stukje DNA op de juiste plek terechtkomt. We maken gebruik van het Adeno-Associated Virus, AAV. De meest succesvolle vector van dit moment.” ?Wat wel kan gebeuren bij het gebruik van zo’n virus, is dat de afweer van de patiënt er in de loop der tijd op gaat reageren. De levercellen die het nieuwe DNA hebben opgenomen, kunnen worden afgebroken door het afweersysteem, waardoor ook de factor IX eiwitproductie weer verloren gaat. Tot nu toe – de AMC-patiënt is in september vorig jaar behandeld – is dat nog niet gebeurd. ?Coppens is dan ook voorzichtig optimistisch: “Als onze studie langdurige expressie laat zien van stollingsfactor IX, dan zou dit wel eens dé behandeling voor deze ziekte kunnen zijn. Maar dan moet blijken dat het een therapie is waarbij de meeste patiënten geen immuunreactie ontwikkelen in de eerste drie maanden en gedurende een lange periode het stollingseiwit produceren.”

www.amc.nl/web/Het-AMC/Nieuws/Nieuwso...

flosz 28 januari 2016 19:33

0

Reactie NVHP: twitter.com/nvhp_nl/status/6927537372...

Bijlage:

flosz 11 februari 2016 21:35

0

AMC Magazine, hem.B&A.
issuu.com/amcamsterdam/docs/amc_magaz...

P.7/8.

Bijlage:

[verwijderd] 7 maart 2016 22:08

0

The FDA approves CSL Behring's IDELVION [Coagulation Factor IX (Recombinant), Albumin Fusion Protein] for the routine prophylaxis of hemophilia B in children and adults to prevent or reduce the frequency of bleeding episodes, on-demand control and prevention of bleeding episodes and the perioperative (around the time of surgery) management of bleeding.

flosz 14 maart 2016 11:23

0

$QURE :Dosing of First Patient in High-Dose Cohort in Phase I/II Hemophilia B Clinical Trial

Amsterdam, the Netherlands, March 14, 2016 — uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that the Company has treated the first patient in the second cohort of its ongoing AMT-060-01 Phase I/II trial in hemophilia B patients. The primary objective of the second cohort is to assess the safety of the systemic administration of a higher dose of uniQure’s AMT-060 gene therapy in hemophilia B patients that present with a severe or moderately-severe disease phenotype. Secondary objectives of the trial include evaluation of Factor IX (FIX) activity levels as well as evaluation of annualized bleeding rates and recombinant FIX usage.
The Company announced preliminary top-line results of the low-dose cohort on January 7th, 2016, showing that AMT-060 was generally well tolerated. Additionally, the first two patients that had completed at least 12 weeks of follow-up showed promising increases in FIX expression levels of 5.5% and 4.5% of normal as of the December 16, 2015 cutoff date, and in four of the five patients dosed the need for continuous, prophylactic rFIX treatment was eliminated as of January 6th, 2016. Including the patients screened and treated in the low-dose cohort, a total of eight patients screened to date for the trial have tested negative for pre-existing anti-AAV5 antibodies. uniQure intends to present an updated analysis of all patients in the low-dose cohort at a scientific conference in the second quarter of 2016.
“Our goal for the second cohort is to evaluate AMT-060’s safety profile at a higher dose and to test our hypothesis that with this dose we could achieve further increases in FIX expression levels,” said Deya Corzo, Senior Vice President and Therapeutic Area Head, Liver/Metabolism. “The early data we announced in January indicate that our proprietary AAV5 viral vector can achieve a clinically relevant level of expression of the FIX transgene. Our data thereby reproduced previously published long-term FIX expression levels seen with a dose comparable to that used in our low-dose cohort with the same gene cassette but using a different vector.”
“The successful dosing of the first patient in the high-dose cohort marks another significant step towards bringing this gene therapy to patients,” said Dan Soland, CEO of uniQure. “With the greenlight from the Data Monitoring Committee after the first cohort, we are excited to be able to move the program forward. We strongly believe that the product profile of AMT-060 has the potential to improve the quality of life of hemophilia B patients.”
The AMT-060-01 Phase I/II study is a 5-year, open-label, uncontrolled, dose-ascending trial that includes two cohorts, with the low-dose cohort using a treatment of 5x1012 gc/kg and the high-dose cohort using 2x1013 gc/kg. AMT-060 consists of a codon-optimized wild type FIX gene and the LP1 liver promoter together with the AAV5 viral vector, manufactured using uniQure’s proprietary insect cell based manufacturing technology. It is administered, without immunosuppressant therapy, through the peripheral vein in a single treatment session for approximately 30 minutes. All patients are screened for pre-existing AAV5 antibodies before treatment and Data Monitoring Committee (DMC) reviews are conducted after each of the first 2 patients in the second cohort.

www.uniqure.com/uploads/News/160314%2...

Bijlage:

flosz 19 mei 2016 12:11

1

$QURE Announces Oral Presentation of Clinical Data from Ongoing Phase I/II Study of AMT-060 in Hemophilia B #EHA16 www.uniqure.com/uploads/News/20160513...

Abstract #S467: First Results from a Dose-Escalating Study with AAV5 Vector Containing Wild Type Human Factor IX Gene Therapy in Patients with Severe or Moderately-Severe Hemophilia B

Bijlage:

flosz 19 mei 2016 12:22

1

FIRST RESULTS FROM A DOSE-ESCALATING STUDY WITH AAV5 VECTOR CONTAINING WILD TYPE HUMAN FACTOR IX GENE THERAPY IN PATIENTS WITH SEVERE OR MODERATELY-SEVERE HAEMOPHILIA B
Author(s): FWG Leebeek, J Schwaeble, K Meijer, M Coppens, P Kampmann, S Krekeler, H Bonig, E Seifried, W Miesbach
(Abstract release date: May 19, 2016) EHA Learning Center. Leebeek F. Jun 11, 2016; 135223
Label: Bleeding disorders

Dr. Frank Leebeek

Contribution

Abstract Rate & Comment (0) Discussion Forum (0)
Abstract: S467

Type: Oral Presentation

Presentation during EHA21: On Saturday, June 11, 2016 from 11:30 - 11:45

Location: Room H4

Background
Gene therapy for haemophilia B offers the potential to convert the disease severity from severe to a mild phenotype through continuous endogenous production of FIX. Adeno-associated viral (AAV) vectors of serotypes 2 and 8 (AAV2 and AAV8) containing the human factor IX (hFIX) gene have been used in previous clinical trials.1-3 A single infusion with AAV8 vector resulted in dose dependent FIX expression for up to 4 years.4 AMT-060 (AAV5-hFIX) consists of an AAV5 vector with an LP1 liver specific promotor, containing a codon-optimised wild type hFIX gene. A potential advantage of AAV5 is the lower prevalence of neutralising antibodies compared to other serotypes.

Aims
This study aims to investigate the safety and efficacy of AMT-060 in adult patients with severe or moderately severe haemophilia B.

Methods
This is an open-label, single dose escalating study in patients with FIX activity = 1-2% of normal, and a severe bleeding phenotype. Five patients were enrolled in the first cohort of AMT-060 5x 1012 gc/kg and a subsequent 5 patients will be enrolled in the second cohort of 2 × 1013 gc/kg. Patients receive AMT-060 via IV infusion over 30 minutes in an in-hospital setting. Safety assessments include treatment related adverse events (AEs) and serious AEs (SAEs). Efficacy assessments include FIX activity, rFIX usage and annualized bleeding rates. We report here preliminary results of the 5 patients treated in the first dose cohort. All patients gave informed consent.

Results
The age of the patients ranged from 35 to 72 years. None of the patients had pre-existing AAV5 antibodies. Four patients had documented FIX activity of <1% and one patient had 1.5%. Four patients had documented haemophiliac arthropathy. All patients were receiving rFIX prophylaxis weekly or twice-weekly prior to treatment with AMT-060. As expected, all 5 patients developed anti-AAV5 antibodies in response to study drug. None of the patients have developed inhibitory antibodies against FIX. Two SAEs have occurred. One patient had an asymptomatic, mild, transient elevation of ALT (peak level at week 10, 61 IU/L; upper limit of normal, 40 IU/L) that resolved after rapid institution of a tapering regimen of prednisolone. Another patient had a self-resolving febrile episode within the first 24 hours of AMT-060 administration. During the first 12 weeks post-gene therapy, 4 out of the 5 patients achieved FIX activity levels that allowed them to discontinue rFIX prophylaxis. FIX activity and other efficacy outcome measures for a minimum of 30 weeks follow-up of the 5 patients in the first dose cohort will be presented.

Conclusion
Treatment of haemophilia B with a single infusion of AMT-060 was well tolerated, and clinically relevant FIX activity has been achieved in the first dose cohort, relieving 4 out of 5 patients from rFIX prophylaxis. The study will continue with enrolment of the second dose cohort as planned. References1. Manno C, Chew A, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe haemophilia B. Blood 2003;101:2963-2972.2. Manno C, Pierce G, Arruda V, et al. Successful transduction of liver in haemophilia by AAV factor IX and limitations imposed by the host immune response. Nat Med 2006;12:342-347.3. Nathwani A, Tuddenham E, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in haemophilia B. N Engl J Med 2011;365:2357-2365.4. Nathwani A, Reiss U, Tuddenham E, et al. Long-term safety and efficacy of factor IX gene therapy in haemophilia B. N Engl J Med2014;371:1994-2004.

Session topic: Bleeding disorders

Keyword(s): Factor IX, Gene therapy, Hemophilia B
learningcenter.ehaweb.org/eha/2016/21...

Bijlage:

flosz 22 juni 2016 12:01

0

Even plakken.

Hem.B. nog steeds "on track"!

www.uniqure.com/uploads/News/160611_A...

Bijlage:

AEX 904,21 0,00 0,00% 09 mei


Germany40^	18.721,40	+0,19%
BEL 20	3.985,40	0,00%
Europe50^	5.063,48	+0,18%
US30^	39.462,80	+0,14%
Nasd100^	18.136,60	+0,10%
US500^	5.221,75	+0,12%
Japan225^	38.201,60	-0,61%
Gold spot	2.356,47	+0,44%
EUR/USD	1,0775	-0,06%
WTI	79,84	+0,29%

AALBERTS NV	0,00%
ABN AMRO BANK...	0,00%
Accsys	0,00%
ACOMO	0,00%
ADYEN NV	0,00%

AALBERTS NV	0,00%
ABN AMRO BANK...	0,00%
Accsys	0,00%
ACOMO	0,00%
ADYEN NV	0,00%

uniQure « Terug naar discussie overzicht

Hemofilie B; nog steeds on track?

Meedoen aan de discussie?

Direct naar Forum

Markt vandaag

Aandelenadviezen van IEX.nl

Stijgers

Dalers